Clinical Trials

Precision drug development*

Through our clinical development strategy, we strive to achieve three fundamental principles. We believe that following these principles may lead to more precise, effective, and safer therapies.

  1. 1. Using companion imaging agents to identify appropriate patients and indications.
  2. 2. Improving the potency of the therapy by using more highly active drugs and more frequent dosing.
  3. 3. Decreasing toxicity through precise targeting so the therapy can be combined with other drugs.

Endocyte is currently sponsoring clinical trials related to several oncology product candidates.

EC1456 Solid Tumors: FOLIC ACID-TUBULYSIN CONJUGATE

 

Phase 1 study of folic acid-tubulysin conjugate EC1456 in patients with advanced solid tumors

EC1169 PSMA Tubulysin

Phase 1 study of a targeting-tubulysin conjugate in patients with recurrent metastatic, castration-resistant prostate cancer (MCRPC)

Medical professionals requesting additional information may contact clinical@endocyte.com

  1. * The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.